New drug research and development of Guizhou Ethnic Pharmaceutical Co., Ltd.

At the early stage of its establishment, the company established the strategy of vigorously promoting the research and development of new ethnic medicine, especially vigorously promoting the research of litsea cubeba series products in Yixinweizhitong capsules, which is the leading policy of the company's new drug research strategy. At present, the products under study are:

1. Six new Chinese medicine "Mimixinle Dropping Pills" for treating cardiovascular diseases have completed a long phase I, II and III clinical study in the past five years. At present, the US Food and Drug Administration is conducting a final review of the production license application for this product. This research has applied for and obtained the national invention patent certificate.

2. The new drug "Guiyang Ai Kang I" developed by our company is conducting comprehensive preliminary basic research, striving to complete the preclinical research by the end of 20 10;

3. Mijiao Jiuxin Dripping Pill, a five-category national new drug for treating cardiovascular diseases, has signed a technical development contract with the National Medicine Laboratory of the National Engineering Research Center for Manufacturing Technology of Solid Preparations of Traditional Chinese Medicine, and it is expected to apply to the State Medical and Drug Administration for clinical examination and approval on 201kloc-0/.

In addition, the company has also carried out extensive cooperation with many scientific research institutions. In May this year, we signed two R&D project contracts with Guiyang Chunke Pharmaceutical Technology R&D Co., Ltd. and Chongqing Institute of Traditional Chinese Medicine: Xinweizhitong Soft Capsule and Xinweizhitong Dropping Pill. At present, the research work is progressing smoothly, and all preclinical research work can be completed as planned in the first half of 20 10.